New Targeted Therapies for Bone Metastases

Allan Lipton, Luis Costa, Paul Sieber, William C. Dougall, Ada Braun

Research output: Chapter in Book/Report/Conference proceedingChapter


A number of targeted agents under investigation or in development have shown promise in the treatment or prevention of bone metastases. Among them is denosumab (XGEVA, Amgen Inc.), a fully human monoclonal antibody targeting the RANK ligand (RANKL) pathway that was approved on 18 November 2010 in the United States (Amgen XGEVA [denosumab] prescribing information, 2012). Denosumab has been proven superior to zoledronic acid in preserving skeletal function and integrity by preventing skeletal complications among patients with bone metastases from solid tumors. Denosumab has demonstrated prolongation of bone metastasis-free survival in men with castration-resistant prostate cancer and is being investigated for this outcome in women with early-stage breast cancer. Another study is prospectively evaluating a potential prolongation of overall survival with denosumab in patients with metastatic lung cancer. Also currently in development are numerous targeted agents that impact the function of the various growth factors released from the bone matrix that stimulate tumor growth, bone destruction, and lead to bone metastases.

Original languageEnglish (US)
Title of host publicationBone Metastases
Subtitle of host publicationA translational and Clinical Approach
EditorsVassilios Vassiliou, Edward Chow, Dimitrios Kardamakis
Number of pages12
StatePublished - 2014

Publication series

NameCancer Metastasis - Biology and Treatment
ISSN (Print)1568-2102

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'New Targeted Therapies for Bone Metastases'. Together they form a unique fingerprint.

Cite this